Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Chiaki, Kiyota, Naomi, Imamura, Yoshinori, Goto, Hideaki, Suto, Hirotaka, Chayahara, Naoko, Toyoda, Masanori, Ito, Yasuhiro, Miya, Akihiro, Miyauchi, Akira, Teshima, Masanori, Otsuki, Naoki, Nibu, Ken-ichi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/
https://www.ncbi.nlm.nih.gov/pubmed/34307122
http://dx.doi.org/10.3389/fonc.2021.638123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/
https://www.ncbi.nlm.nih.gov/pubmed/34307122
http://dx.doi.org/10.3389/fonc.2021.638123

Ejemplares similares